Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 10, 2006, Pages 1473-1477

  Gunaratnam, N T ^a   Jessup, T P ^b   Inadomi, J ^c   Lascewski, D P ^a  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; TIME FACTORS;

EID: 33646260477     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02911.x     Document Type: Article

References (16)

1. A Gallup Organizational National Survey Heartburn Across America Princeton, NJ The Gallup Organization, Inc 1988
2. Eisen G The epidemiology of gastroesophageal reflux disease: what we know and what we need to know Amer J Gastro 2001 96 Suppl. 8 S16 8
3. Johanson JF Epidemiology of esophageal and supraesophageal reflux injuries Amer J Med 2000 108 Suppl. 4A 99S 103S
4. Locke GR Talley NJ Fett SL Zinsmeister AR Melton LJ Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota Gastroenterology 1997 112 1448 56
5. Frank L Kleinman L Ganoczy D et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life Digest Dis Sci 2000 45 809 18
6. Talley NJ Weaver AL Zinsmeister AR Melton LJ Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders Amer J Epidemiol 1992 136 165 77
7. Greenberger NJ Update in gastroenterology Ann Intern Med 1998 129 309 16
8. Bloom BS Jayadevappa R Wahl P Cacciamanni J Time trends in cost of caring for people with gastroesophageal reflux disease Amer J Gastro 2001 96 Suppl. 8 S64 9
9. Fendrick AM Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective Amer J Gastro 2001 96 Suppl. 8 S29 33
10. Vigneri S Termini R Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis N Engl J Med 1995 333 1106 10
11. Venables TL Newland RD Patel AC Hole J Wilcock C Turbitt ML Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice Scand J Gastroenterol 1997 32 965 73
12. Wolfe MM Sachs G Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome Gastroenterology 2000 118 S9 S31
13. Hatlebakk JG Katz PO Castell DO Gastroesophageal reflux disease: medical therapy: management of the refractory patient Gastro Clinics 1999 28 847 60
14. Katz PO Lessons learned from intragastric pH monitoring J Clin Gastroenterol 2001 33 107 13
15. Kuo B Castell DO Optimal dosing of omeprazole 40 mg daily: effects of gastric and esophageal pH and serum gastrin in healthy controls Amer J Gastroenterol 1996 91 1532 8
16. Hatlebakk JG Katz PO Camacho-Lobato L Castell DO Proton pump inhibitors: better acid suppression when taken before a meal than without a meal Aliment Pharm Ther 2000 14 1267 72